Trial Profile
An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Biomarker
- Acronyms 034OLE; 03OLE; GBT440-034 (UK)
- Sponsors Global Blood Therapeutics; Pfizer
- 12 Dec 2023 Updated results of 4 Years of Safety and Efficacy, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 28 Jul 2023 Planned End Date changed from 1 Oct 2024 to 31 Dec 2024.
- 28 Jul 2023 Planned primary completion date changed from 1 Oct 2024 to 31 Dec 2024.